- Gland Pharma has signed a Manufacturing and Supply Agreement with a global pharmaceutical company covering technology transfer, manufacturing, and supply of 55 sterile injectable SKUs for global markets.
- The agreement is expected to generate annualized revenue of approximately $90 million–$100 million once fully commercialized, with revenue expected to begin in 2029.
Gland Pharma has entered into a strategic Manufacturing and Supply Agreement (MSA) with a global pharmaceutical company to provide technology transfer, manufacturing, and supply of sterile injectable products for global markets. The agreement covers 55 stock keeping units (SKUs) that will be manufactured across three of Gland Pharma’s facilities. Technology transfer activities are expected to be completed within two years, with commercial revenue anticipated to begin in calendar year 2029. Once the portfolio is fully commercialized, the agreement is expected to generate annualized revenue of approximately $90 million to $100 million.
The partnership will operate under a full-service CDMO and contract manufacturing model. Gland Pharma will provide technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply. The company will also deliver integrated development, manufacturing, quality, and regulatory support as a single-source solution for its partner.
“We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma’s development, technology transfer, manufacturing, and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth.”
Srinivas Sadu, Executive Chairman of Gland Pharma Limited
